Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in chinese patients with non-small cell lung cancer

Chinese Medical Journal

Volumn 124, Issue 13, 2011, Pages 1933-1938

  Wang, Han Ping ^a   Zhang, Li ^a   Wang, Yin Xiang ^b   Tan, Fen Lai ^b   Xia, Ying ^a   Ren, Guan Jun ^a   Hu, Pei ^a   Jiang, Ji ^a   Wang, Meng Zhao ^a   Xiao, Yi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Zhejiang Beta Pharma Inc   (China)

Author keywords

Epidermal growth factor receptor; Icotinib; Safety; Tolerability; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ICOTINIB; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; SMOKING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79960034992     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.13.003     Document Type: Article

References (25)

1. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
2. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
3. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited anti proliferative effects and absence of apoptosis associated with persistent activity of extra cellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
5. Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM. Response to gefitinib and erlotinib in non-small cell lung cancer: a retrospective study. BMC Cancer 2009; 9: 333.
6. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treatednon-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
7. Park K, Goto K. A review of the benefit-risk profile ofgefitinib in Asian patients with advanced non-small-cell lungcancer. Curr Med Res Opin 2006; 22: 561-573.
8. Armour A. Gefitinib in advanced non-small cell lung cancer:clinical experience in patients of Asian origin. Asia Pac J ClinOncol 2007; 3: 66-78.
9. Yang CH. EGFR tyrosine kinase inhibitors for the treatmentof NSCLC in East Asia: present and future. Lung Cancer 2008; 60 Suppl 2: S23-S30
10. Sasaki H, Okuda K, Takada M, Kawahara M, Kitahara N, Matsumura A, et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J CancerRes Clin Oncol 2008; 134: 1371-1376.
11. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR-mutant lung cancer in women and in east Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res 2008; 14: 4079-4084.
12. Response evaluation criteria in solid tumors (RECIST) quick reference. (Accessed February 20, 2010 at http://www.nci.nih.gov/bip/RECIST.htm)
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsivenessof non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139.
14. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
15. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
16. Cappuzzo F, Varella-Garcia M, Shigematsu J, Domenichini I, Bartolini S, Ceresoli GL, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. J Clin Oncol 2005; 23: 5007-5018.
17. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the anti tumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822.
18. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-over expressing tumor cells canbe overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. ClinCancer Res 2003; 9: 4340-4346.
19. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
20. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa)tablets. Oncologist 2003; 8: 303-306.
21. Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005; 41: 772-789.
22. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-1314.
23. Zhou ZT, Xu XH, Wei Q, Lu MQ, Wang J, Wen CH. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 2009; 64:1123-1127.
24. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J Natl Cancer Inst 2005: 97: 339-346.
25. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-2568.